CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
ObesityLaparoscopic Gastric Bypass SurgerySurgical ConditionsRespiratory FunctionCerebral Tissue Oxygenation
Interventions
DRUG

deep neuromuscular blockade with rocuronium, reversal with sugammadex

after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.

DRUG

normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine

After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.

Trial Locations (1)

3600

Ziekenhuis Oost-Limburg, Genk

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ziekenhuis Oost-Limburg

OTHER

NCT01748643 - CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity | Biotech Hunter | Biotech Hunter